Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun:116:105750.
doi: 10.1016/j.ebiom.2025.105750. Epub 2025 May 28.

Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features

Collaborators, Affiliations

Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features

Shannon Doyle et al. EBioMedicine. 2025 Jun.

Abstract

Background: Ductal Carcinoma In Situ (DCIS) can progress to ipsilateral invasive breast cancer (IBC) but over 75% of DCIS lesions do not progress if untreated. Currently, DCIS that might progress to IBC cannot reliably be identified. Therefore, most patients with DCIS undergo treatment resembling IBC. To facilitate identification of low-risk DCIS, we developed deep learning models using histology whole-slide images (WSIs) and clinico-pathological data.

Methods: We predicted invasive recurrence in patients with primary, pure DCIS treated with breast-conserving surgery using clinical Cox proportional hazards models and deep learning. Deep learning models were trained end-to-end with only WSIs or in combination with clinical data (integrative). We employed nested k-fold cross-validation (k = 5) on a Dutch multicentre dataset (n = 558). Models were also tested on the UK-based Sloane dataset (n = 94).

Findings: Evaluated over 20 years on the Dutch dataset, deep learning models using only WSIs effectively stratified patients into low-risk (no recurrence) and high-risk (invasive recurrence) groups (negative predictive value (NPV) = 0.79 (95% CI: 0.74-0.83); hazard ratio (HR) = 4.48 (95% CI: 3.41-5.88, p < 0.0001); area under the receiver operating characteristic curve (AUC) = 0.75 (95% CI: 0.70-0.79)). Integrative models achieved similar results with slightly enhanced hazard ratios compared to the image-only models (NPV = 0.77 (95% CI 0.73-0.82); HR = 4.85 (95% CI 3.65-6.45, p < 0.0001); AUC = 0.75 (95% CI 0.7-0.79)). In contrast, clinical models were borderline significant (NPV = 0.64 (95% CI 0.59-0.69); HR = 1.37 (95% CI 1.03-1.81, p = 0.041); AUC = 0.57 (95% CI 0.52-0.62)). Furthermore, external validation of the models was unsuccessful, limited by the small size and low number of cases (22/94) in our external dataset, WSI quality, as well as the lack of well-annotated datasets that allow robust validation.

Interpretation: Deep learning models using routinely processed WSIs hold promise for DCIS risk stratification, while the benefits of integrating clinical data merit further investigation. Obtaining a larger, high-quality external multicentre dataset would be highly valuable, as successful generalisation of these models could demonstrate their potential to reduce overtreatment in DCIS by enabling active surveillance for women at low risk.

Funding: Cancer Research UK, the Dutch Cancer Society (KWF), and the Dutch Ministry of Health, Welfare and Sport.

Keywords: Deep learning; Ductal carcinoma in situ; Multiomic integration; Risk prediction.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JT declares being a share owner of Ellogon.AI; consulting for ScreenPoint Medical (all active). JT received support to attend II-ON BMS conference. JT is also a member of the Dutch Cancer Foundation KWF—Smart Measurement committee, as well as Dutch organisation for scientific research—Veni Committee. All other authors declare no competing interests. The consortium was funded by Cancer Grand Challenges, an initiative from Cancer Research UK and the National Cancer Institute, under project Cancer Grand Challenge PRECISION (C38317/A24043).

Figures

Fig. 1
Fig. 1
Flowchart of patient inclusion. Dutch dataset (left); Sloane dataset (right).
Fig. 2
Fig. 2
Pipeline of the deep learning models. Tissue areas of whole-slide images (WSIs) are segmented and tiled without overlap. Tiles are normalised using ImageNet normalisation and processed through a ResNet18 encoder pre-trained on ImageNet. In the integrative models, tile-level features are concatenated with patient-level clinical variables; otherwise, the model operates as an image-only model. These combined features are fed into a multi-layer perceptron to predict patient risk, with end-to-end training occurring using multi-instance learning.
Fig. 3
Fig. 3
Kaplan–Meier curves for models evaluated on 20-year follow-up in the Dutch test cohort. (a) Image-only model, (b) Integrative model, (c) Clinical-basic Cox-PH model. The curves are based on combined predictions from models in outer cross-validation. The shaded area represents 95% confidence intervals. Abbreviations: low: predicted low-risk group; high: predicted high-risk group; HR: hazard ratio.

References

    1. van Seijen M., Lips E.H., Thompson A.M., et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019;121(4):285–292. - PMC - PubMed
    1. Maxwell A.J., Hilton B., Clements K., et al. Unresected screen-detected ductal carcinoma in situ: outcomes of 311 women in the Forget-Me-Not 2 study. Breast Edinb Scotl. 2022;61:145–155. - PMC - PubMed
    1. Chen Q., Campbell I., Elwood M., Cavadino A., Aye P.S., Tin Tin S. Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis. Breast Cancer Res Treat. 2024;208(2):237–251. - PMC - PubMed
    1. Ryser M.D., Weaver D.L., Zhao F., et al. Cancer outcomes in DCIS patients without locoregional treatment. J Natl Cancer Inst. 2019;111(9):952–960. - PMC - PubMed
    1. van Seijen M., Lips E.H., Fu L., et al. Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. Br J Cancer. 2021;125(10):1443–1449. - PMC - PubMed